<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02893098</url>
  </required_header>
  <id_info>
    <org_study_id>HU-025 P3</org_study_id>
    <nct_id>NCT02893098</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of Humia Inj. in Patients With Symptomatic Osteoarthritis of the Knee</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huons Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huons Co.,Ltd.</source>
  <brief_summary>
    <textblock>
      A Multi-Centre, Parallel, Double-Blind, Active comparator, Randomised phase III Clinical
      Trial
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline of Weight-bearing pain (100mm-VAS)</measure>
    <time_frame>Week 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of Weight-bearing pain (100mm-VAS)</measure>
    <time_frame>Weeks 3, 8, 14, and 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Visit 8 of Weight-bearing pain (100mm-VAS)</measure>
    <time_frame>Week 38</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Examination : Swelling</measure>
    <time_frame>Weeks 0, 3, 8, 14, 26, and 38</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Examination : Tenderness on pressure</measure>
    <time_frame>Weeks 0,3,8,14,26,and 38</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Examination : Range of motion</measure>
    <time_frame>Weeks 0, 3, 8, 14, 26, and 38</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of rescue medication</measure>
    <time_frame>Weeks 0, 1, 2, 3, 8, 14, 26, and 38</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion (%) of patients taking rescue medication</measure>
    <time_frame>Weeks 0, 1, 2, 3, 8, 14, 26, and 38</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder Rate</measure>
    <time_frame>Week 14</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">232</enrollment>
  <condition>Osteoarthritis of Knee</condition>
  <arm_group>
    <arm_group_label>Humia inj.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with symptomatic Primary Osteoarthritis of Knee received a single injection of 3ml Humia inj.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Hyal Plus inj.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants (Control Group) with symptomatic Primary Osteoarthritis of Knee received single injection of 2ml High Hyal Plus inj. given weekly for 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humia inj.</intervention_name>
    <description>Single injection of 3mL Humia inj.
Dummy: Single injection 2ml Normal Saline inj. given weekly for 2 weeks</description>
    <arm_group_label>Humia inj.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High hyal Plus inj.</intervention_name>
    <description>Single Injection of 2mL High hyal Plus inj. given weekly for 3 weeks</description>
    <arm_group_label>High Hyal Plus inj.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary knee osteoarthritis confirmed clinically and radiologically according to
             American College of Rheumatology criteria have joint pain

          -  Kellgren-Lawrence Grade Ⅰ to Ⅲ confirmed radiologically within 6 months

          -  Knee pain under weight-bearing pain(100mm-VAS) greater than 40mm

          -  Able to walk without assistive devices

          -  Patients willing and able to provide signed informed consent after the nature of the
             study has been explained

        Exclusion criteria:

          -  Body Mass Index (BMI) &gt; 32

          -  History of rheumatoid arthritis or other inflammatory arthritis in knee articular
             cavity

          -  Systemic Intravenous Steroid injection within 1 month, intra-articular corticosteroid
             injection within 3 months or hyaluronate injection within 6 months

          -  Has clinically severe tense effusion of the target knee diagnosed Positive according
             to Patella tap test

          -  Undergo Knee Replacement Surgery of the target knee
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Huons</name>
      <address>
        <city>Ansan-si</city>
        <state>Gyeonggi-do</state>
        <zip>15588</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2016</study_first_submitted>
  <study_first_submitted_qc>September 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

